As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.
7 Analysts have issued a Finch Therapeutics Group Inc forecast:
7 Analysts have issued a Finch Therapeutics Group Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -20 -20 |
72%
72%
|
EBIT (Operating Income) EBIT | -20 -20 |
74%
74%
|
Net Profit | -14 -14 |
90%
90%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in September 2017 and is headquartered in Somerville, MA.
Head office | United States |
CEO | Matthew Blischak |
Employees | 1 |
Founded | 2014 |
Website | finchtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.